Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
Autor: | Jennifer K. Scherman, Paul E. Schwenn, Daniel F. Hermens, Cyrana C. Gallay, Emma Jensen, Cian Yang, Adem Can, Monique Jones, Megan Dutton, Denise Beaudequin, Jim Lagopoulos |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Adult
Male Suicide Prevention medicine.medical_specialty Scientific community Pilot Projects Article Suicidal Ideation lcsh:RC321-571 03 medical and health sciences Cellular and Molecular Neuroscience Route of administration 0302 clinical medicine Oral administration Internal medicine medicine Suicide ideation Humans Ketamine Suicidal ideation lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Biological Psychiatry Psychiatric Status Rating Scales Depressive Disorder Major Depression business.industry Low dose Alternative treatment 030227 psychiatry Psychiatry and Mental health Female medicine.symptom Open label business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Translational Psychiatry, Vol 11, Iss 1, Pp 1-9 (2021) Translational Psychiatry |
ISSN: | 2158-3188 |
Popis: | Recently, low-dose ketamine has been proposed as a rapid-acting treatment option for suicidality. The majority of studies to date have utilised intravenous (IV) ketamine, however, this route of administration has limitations. On the other hand, oral ketamine can be administered in a range of settings, which is important in treating suicidality, although studies as to safety and feasibility are lacking. n = 32 adults (aged 22–72 years; 53% female) with chronic suicidal thoughts participated in the Oral Ketamine Trial on Suicidality (OKTOS), an open-label trial of sub-anaesthetic doses of oral ketamine over 6 weeks. Participants commenced with 0.5 mg/kg of ketamine, which was titrated to a maximum 3.0 mg/kg. Follow-up assessments occurred at 4 weeks after the final dose. The primary outcome measure was the Beck Scale for Suicide Ideation (BSS) and secondary measures included scales for suicidality and depressive symptoms, and measures of functioning and well-being. Mean BSS scores significantly reduced from a high level of suicidal ideation at the pre-ketamine (week 0) timepoint to below the clinical threshold at the post-ketamine (week 6) timepoint. The proportion of participants that achieved clinical improvement within the first 6 weeks was 69%, whereas 50% achieved a significant improvement by the follow-up (week 10) timepoint. Six weeks of oral ketamine treatment in participants with chronic suicidality led to significant reduction in suicidal ideation. The response observed in this study is consistent with IV ketamine trials, suggesting that oral administration is a feasible and tolerable alternative treatment for chronic suicidality. |
Databáze: | OpenAIRE |
Externí odkaz: |